tbuckley/cabot-search huggingface dataset:
Allogeneic Stem Cell Transplantation for Primary or Secondary Myelofibrosis: A Retrospective Intent-to-Treat Analysis and Impact of Mutational Status and JAK1/2 Inhibitor Ruxolitinib Prescription in Patients Who Cannot Proceed to Transplantation
Authors: Elsa Lestang, Pierre Peterlin, Yannick Le Bris, Jacques Delaunay, Viviane Dubruille, Nicolas Blin, Beatrice Mahe, Thomas Gastinne, Alice Garnier, Cyrille Touzeau, Maud Voldoire, Herve Maisonneuve, Marie C Bene, Steven Le Gouill, Noel Milpied, Mohamad Mohty, Philippe Moreau, Thierry Guillaume, Patrice Chevallier
Journal: Blood (2015)
The Potency of Nef-Mediated SERINC5 Antagonism Correlates with the Prevalence of Primate Lentiviruses in the Wild
Authors: Anke Heigele, Dorota Kmiec, Kerstin Regensburger, Simon Langer, Lukas Peiffer, Christina M. Stürzel, Daniel Sauter, Martine Peeters, Massimo Pizzato, Gerald H. Learn, Beatrice H. Hahn, Frank Kirchhoff
Journal: Cell Host & Microbe (2016)
Whole exome sequencing in families with CLL detects a variant in Integrin β 2 associated with disease susceptibility
Authors: Lynn R. Goldin, Mary L. McMaster, Melissa Rotunno, Sarah E. M. Herman, Kristine Jones, Bin Zhu, Joseph Boland, Laurie Burdett, Belynda Hicks, Sarangan Ravichandran, Brian T. Luke, Meredith Yeager, Laura Fontaine, Alisa M. Goldstein, Stephen J. Chanock, Margaret A. Tucker, Adrian Wiestner, Gerald Marti, Neil E. Caporaso
Journal: Blood (2016)
Fast, Accurate and Automatic Ancient Nucleosome and Methylation Maps with epiPALEOMIX
Authors: Kristian Hanghøj, Andaine Seguin-Orlando, Mikkel Schubert, Tobias Madsen, Jakob Skou Pedersen, Eske Willerslev, Ludovic Orlando
Journal: Molecular Biology and Evolution (2016)

The first epigenomes from archaic hominins (AH) and ancient anatomically modern humans (AMH) have recently been characterized, based, however, on a limited number of samples. The extent to which ancient genome-wide epigenetic landscapes can be reconstructed thus remains contentious. Here, we present epiPALEOMIX, an open-source and user-friendly pipeline that exploits post-mortem DNA degradation patterns to reconstruct ancient methylomes and nucleosome maps from shotgun and/or capture-enrichment data. Applying epiPALEOMIX to the sequence data underlying 35 ancient genomes including AMH, AH, equids and aurochs, we investigate the temporal, geographical and preservation range of ancient epigenetic signatures. We first assess the quality of inferred ancient epigenetic signatures within well-characterized genomic regions. We find that tissue-specific methylation signatures can be obtained across a wider range of DNA preparation types than previously thought, including when no particular experimental procedures have been used to remove deaminated cytosines prior to sequencing. We identify a large subset of samples for which DNA associated with nucleosomes is protected from post-mortem degradation, and nucleosome positioning patterns can be reconstructed. Finally, we describe parameters and conditions such as DNA damage levels and sequencing depth that limit the preservation of epigenetic signatures in ancient samples. When such conditions are met, we propose that epigenetic profiles of CTCF binding regions can be used to help data authentication. Our work, including epiPALEOMIX, opens for further investigations of ancient epigenomes through time especially aimed at tracking possible epigenetic changes during major evolutionary, environmental, socioeconomic, and cultural shifts.
Allogeneic (Allo-) or Autologous (Auto-) Peripheral Blood Stem Cell Transplantation (SCT) Randomized Versus a Second Intensive Consolidation after a Common Induction and Consolidation Course in Patients with Bad Prognosis Myelodysplastic Syndromes and Acute Myelogenous Leukemia Following MDS of More Than 6 Months Duration: The Final Analysis of a Joint Study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukemia Groups.
Authors: T.M. De Witte, A. Hagemeijer, S. Suciu, A. Belhabri, M. Delforge, C. Aul, M. Aivado, D. Selleslag, H. Schouten, A. Ferrant, H. Biersack, S. Amadori, P. Muus, U. Jehn, F. Beeldens, J. Jansen, E. Hellstrom-Lindberg, T. Kovacsovics, U. Hess, P. Wijermans, G. Ossenkoppele, A. Gratwohl, J.-P. Marie, R. Willemze
Journal: Blood (2005)
Reversal of Vascular Calcification and Aneurysms in a Rat Model Using Dual Targeted Therapy with EDTA- and PGG-Loaded Nanoparticles
Authors: Nasim Nosoudi, Aniqa Chowdhury, Steven Siclari, Saketh Karamched, Vaideesh Parasaram, Joe Parrish, Patrick Gerard, Narendra Vyavahare
Journal: Theranostics (2016)

Degeneration of elastic lamina and vascular calcification are common features of vascular pathology such as aortic aneurysms.We tested whether dual therapy with targeted nanoparticles (NPs) can remove mineral deposits (by delivery of a chelating agent, ethylene diamine tetraacetic acid (EDTA)) and restore elastic lamina (by delivery of a polyphenol, pentagalloyl glucose (PGG)) to reverse moderate aneurysm development.EDTA followed by PGG NP delivery led to reduction in macrophage recruitment, matrix metalloproteinase (MMP) activity, elastin degradation and calcification in the aorta as compared to delivery of control blank NPs.Such dual therapy restored vascular elastic lamina and improved vascular function as observed by improvement in circumferential strain.Therefore, dual targeted therapy may be an attractive option to remove mineral deposits and restore healthy arterial structures in moderately developed aneurysms.
LAMTOR2 Regulates Stem Cell Maintenance and Acts in Lineage Choice By Modulating Cytokine Receptor-Mediated Signaling
Authors: Daniel Kotlarz, Gudrun Brandes, Schwarzer Adrian, Glage Silke, Büsche Guntram, Pfeifer Dietmar, Lukas A Huber, Christoph Klein
Journal: Blood (2014)
Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers
Authors: Pietro Carotenuto, Matteo Fassan, Rosantony Pandolfo, Andrea Lampis, Caterina Vicentini, Luciano Cascione, Viola Paulus-Hock, Luke Boulter, Rachel Guest, Luca Quagliata, Jens Claus Hahne, Rachel Ridgway, Tam Jamieson, Dimitris Athineos, Angelo Veronese, Rosa Visone, Claudio Murgia, Giulia Ferrari, Vincenza Guzzardo, Thomas Ronald Jeffry Evans, Martin MacLeod, Gui Ji Feng, Trevor Dale, Massimo Negrini, Stuart J Forbes, Luigi Terracciano, Aldo Scarpa, Tushar Patel, Nicola Valeri, Paul Workman, Owen Sansom, Chiara Braconi
Journal: Gut (2016)

Objective Transcribed-ultraconserved regions (T-UCR) are long non-coding RNAs which are conserved across species and are involved in carcinogenesis. We studied T-UCRs downstream of the Wnt/β-catenin pathway in liver cancer. Design Hypomorphic Apc mice ( Apcfl/fl ) and thiocetamide (TAA)-treated rats developed Wnt/β-catenin dependent hepatocarcinoma (HCC) and cholangiocarcinoma (CCA), respectively. T-UCR expression was assessed by microarray, real-time PCR and in situ hybridisation. Results Overexpression of the T-UCR uc.158− could differentiate Wnt/β-catenin dependent HCC from normal liver and from β-catenin negative diethylnitrosamine (DEN)-induced HCC. uc.158− was overexpressed in human HepG2 versus Huh7 cells in line with activation of the Wnt pathway. In vitro modulation of β-catenin altered uc.158− expression in human malignant hepatocytes. uc.158− expression was increased in CTNNB1 -mutated human HCCs compared with non-mutated human HCCs, and in human HCC with nuclear localisation of β-catenin. uc.158− was increased in TAA rat CCA and reduced after treatment with Wnt/β-catenin inhibitors. uc.158− expression was negative in human normal liver and biliary epithelia, while it was increased in human CCA in two different cohorts. Locked nucleic acid-mediated inhibition of uc.158− reduced anchorage cell growth, 3D-spheroid formation and spheroid-based cell migration, and increased apoptosis in HepG2 and SW1 cells. miR-193b was predicted to have binding sites within the uc.158− sequence. Modulation of uc.158− changed miR-193b expression in human malignant hepatocytes. Co-transfection of uc.158− inhibitor and anti-miR-193b rescued the effect of uc.158− inhibition on cell viability. Conclusions We showed that uc.158− is activated by the Wnt pathway in liver cancers and drives their growth. Thus, it may represent a promising target for the development of novel therapeutics.
Pathophysiology of sepsis-induced myocardial dysfunction
Authors: Xiuxiu Lv, Huadong Wang
Journal: Military Medical Research (2016)

Sepsis-induced myocardial dysfunction is a common complication in septic patients and is associated with increased mortality. In the clinical setting, it was once believed that myocardial dysfunction was not a major pathological process in the septic patients, at least in part, due to the unavailability of suitable clinical markers to assess intrinsic myocardial function during sepsis. Although sepsis-induced myocardial dysfunction has been studied in clinical and basic research for more than 30 years, its pathophysiology is not completely understood, and no specific therapies for this disorder exist. The purpose of this review is to summarize our current knowledge of sepsis-induced myocardial dysfunction with a special focus on pathogenesis and clinical characteristics.
Chronic kidney disease is associated with increased mortality, bleeding, and ischemic events in moderate and high-risk patients with acute coronary syndromes: An ACUITY substudy
Authors: Roxana Mehran, Ajay J Kirtane, George Dangas, Magnus Ohman, Stuart Pocock, Bernard Gersh, Michael Bertrand, Martial Hamon, Steven Manoukian, James Hoekstra, Charles Pollack, Walter Desmet, Frederick Feit, Joseph Stella, Angel Cequier, Thomas Stuckey, David Cohen, Gregg W Stone
Journal: Journal of the American College of Cardiology (2007)
The CNIC
Authors: Valentín Fuster, Borja Ibáñez, Vicente Andrés
Journal: Circulation Research (2016)

has rapidly established itself as a leading international center for cardiovascular research through pioneering leadership and a research strategy that cuts across disciplinary boundaries. Mission and leadershipOver the past 10 years, the CNIC has built an unrivalled infrastructure and a powerful, cross-disciplinary research base that embraces multiple disciplines and both population and patient studies.One of the keys to this achievement is the commitment of national government to building a flagship research institute to tackle the cardiovascular disease (CVD) epidemic.But the public purse is only part of the story; most importantly the CNIC is funded through an innovative public-private financing structure which injects not only added financial security but also the wide-ranging business and management expertise of some of the most prominent Spanish businesses (Pro CNIC Foundation, see below).
Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).
Authors: Ghassan K. Abou-Alfa, Ann-Lii Cheng, Tim Meyer, Anthony B. El-Khoueiry, Masafumi Ikeda, Hoo Geun Chun, Junji Furuse, Jennifer J. Knox, Takuji Okusaka, Jerry Ping, Anne E. Borgman-Hagey, Robin Kate Kelley
Journal: Journal of Clinical Oncology (2015)

TPS496 Background: Currently, there are no approved systemic therapies for patients with advanced hepatocellular carcinoma (HCC) who fail sorafenib. Cabozantinib is an oral receptor tyrosine kinase inhibitor (TKI) with activity against tyrosine kinases including MET, RET and VEGFRs. MET and VEGFR signaling have been implicated in tumor neo-angiogenesis and invasion. MET is overexpressed in HCC compared with non-tumor liver tissue, with higher MET expression linked to poor prognosis. Cabozantinib prolonged survival in a MET-driven transgenic mouse model of HCC, and has demonstrated clinical activity in multiple solid tumor types, including 41 subjects with advanced HCC treated in a phase 2 randomized discontinuation study. Methods: This phase 3, randomized, double-blind study evaluates the efficacy and safety of cabozantinib compared with placebo in subjects with advanced HCC previously treated with sorafenib and have progressed following 1-2 prior systemic treatments for HCC. Subjects must be ≥ 18 year old, have Child-Pugh Score of A and ECOG PS ≤ 1. Subjects are randomized 2:1 to receive either cabozantinib or placebo. Stratification factors are etiology of disease, geographic region and the presence of extrahepatic spread of disease and/or macrovascular invasion. The primary endpoint is overall survival. Secondary endpoints are progression-free survival and objective response rate by RECIST 1.1. Additional endpoints include safety, tolerability, circulating tumor cells, serum bone markers and plasma biomarkers, effects on bony disease assessed by bone scan and health-related quality of life (HRQoL) using the EuroQol Health questionnaire (EQ-5D-5L). Enrollment was initiated in September 2013. Target recruitment is 760 subjects. A total of 621 events planned with 2 interim analyses (at 311 and 466 events) would provide 90% power to detect a 31.6% increase in OS (HR=0.76). Clinical trial information: NCT01908426.
Enhanced performance feedback and patient participation to improve hand hygiene compliance of health-care workers in the setting of established multimodal promotion: a single-centre, cluster randomised controlled trial
Authors: Andrew James Stewardson, Hugo Sax, Angèle Gayet-Ageron, Sylvie Touveneau, Yves Longtin, Walter Zingg, Didier Pittet
Journal: The Lancet Infectious Diseases (2016)
A randomized, double-blind, placebo-controlled study to assess siltuximab (CNTO 328, an anti-IL-6) in patients with multicentric Castleman's disease.
Authors: J. Vermeulen, M. Qi, J. B. Herring, J. Flisak, H. M. Prince, J. Rossi, M. J. Cornfeld, F. Van Rhee
Journal: Journal of Clinical Oncology (2010)

TPS186 Background: Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder in which dysregulated production of interleukin (IL)-6 results in lymph node enlargement and debilitating symptoms, including systemic inflammatory manifestations (e.g., fever, fatigue, and weight loss), autoimmune phenomena, and markedly abnormal laboratory findings (e.g., anemia, hyper-γ-globulinemia, hypoalbuminemia, thrombocytosis and increases in acute-phase proteins like CRP, ESR and fibrinogen). There is currently no approved systemic treatment for MCD. Siltuximab is a chimeric monoclonal antibody that binds to IL-6 with both high specificity and high affinity while neutralizing the biological activity. In an ongoing phase I study, high objective tumor response rate (52%) and clinical benefit rate (78%) have been observed in subjects with MCD with a favorable safety profile (van Rhee et al. Blood 2008, 1008). These results have prompted a randomized, double-blind, placebo-controlled study to definitively assess the efficacy and safety of siltuximab in combination with best supportive care (BSC) compared with BSC in patients with MCD. Methods: Eligibility includes symptomatic, measurable MCD who are HIV- and HHV-8-negative. Patients with skin lesions only, prior lymphoma, prior exposure to IL-6 or IL-6 receptor targeted treatment are excluded. Patients can be enrolled if they are receiving stable doses of corticosteroids (<1 mg/kg/d of prednisone or equivalent). Approximately 78 patients will be randomly assigned in a 1:2 ratio to placebo + BSC or to CNTO 328 + BSC and will receive siltuximab (11 mg/kg) or placebo in a 1-hour IV infusion every 3 weeks. The primary objective is to evaluate durable tumor and symptomatic response in the intent-to-treat population. Secondary objectives include additional efficacy measures, safety, patient reported outcomes, and pharmacologic assessment. Status: This is the first randomized placebo controlled study to be conducted in MCD. The rarity of the disease and variable clinical course pose unique challenges. The study is now open for enrollment in multiple countries throughout the world. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Centocor Ortho Biotech Centocor Ortho Biotech, Johnson & Johnson, Novartis Johnson & Johnson Celgene, IMER, Optum Health Centocor Ortho Biotech, Johnson & Johnson, Protein Design Labs
Expanding the Range of Diagnosable Autoimmune Encephalopathies and Encephalomyelopathies
Authors: Robert P. Lisak
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Impact of Age, Therapy and Molecular Profile in Myelofibrosis Patients. Analysis on 123 Patients from a Single Italian Haematological Center
Authors: Giulia Benevolo, Eloise Beggiato, Ludovica Riera, Andrea Evangelista, Anna Campana, Barbara Nicolino, Maura Nicolosi, Lucia Biale, Dario Ferrero, Umberto Vitolo
Journal: Blood (2015)
Versatile pH-response Micelles with High Cell-Penetrating Helical Diblock Copolymers for Photoacoustic Imaging Guided Synergistic Chemo-Photothermal Therapy
Authors: Shengyu Shi, Yajing Liu, Yu Chen, Zhihuang Zhang, Yunsheng Ding, Zongquan Wu, Jun Yin, Liming Nie
Journal: Theranostics (2016)

With high optical absorption efficiency, near infrared (NIR) dyes have been proposed as theranostic agents for fluorescence imaging, photoacoustic imaging (PAI), and photothermal therapy (PTT). However, inherent hydrophobicity and short circulation time of small molecule hinder the further biomedical application. Herein smart amphiphilic copolymer was synthesized containing IR780/camptothecin@poly(ε-caprolactone) (IR780/CPT@PCL) as core, helical poly(phenyl isocyanide) (PPI) blocks as shell with the pH-responsive rhodamine B (RhB) moieties in the core-shell interface. With hydrophilic helical PPI coronas, these micelles present significantly enhanced cell-penetrating capacity that plays a key role in facilitating intracellular delivery of various cargos. By encapsulating CPT and IR780 molecules, the multifunctional self-assemble probe has huge potential to realize functional cooperativity and adaptability for cancer diagnosis and therapy. The in vitro and in vivo experimental results demonstrate that the pH-triggered fluorescent responsiveness and strong acoustic generation permit them efficient fluorescent and PA signal sensing for cancer diagnosis. Moreover, with 808 nm laser irradiation, the generated heat significantly improves the drug release from PCL core, leading to synergetic chemo-photothermal therapy and decreases tumor recurrence rates in mice. Overall, the biocompatible multifunctional micelles with these combined advantages can potentially be utilized for PAI guided disease diagnosis and tumor ablation.
Methods to address cancer disparities for Native Americans in western South Dakota.
Authors: Daniel G. Petereit
Journal: Cancer Research (2006)

FO01-02   Native Americans present with more advanced stages of cancer and, therefore, suffer from higher cancer mortality rates compared to non-Indians. Cancer is the second leading cause of death for Native Americans (NA) over 45. A five-year grant was awarded from the National Cancer Institute to research methods of improving cancer treatment and outcomes for Native Americans in Western, South Dakota. This program consists of patient navigation, clinical trials, surveys, and a molecular study to address these complex issues. Patient navigators assist NAs on each reservation through community education, access to health care and support as they go through cancer treatments. It is hypothesized that a major barrier for NAs receiving health care is geographic distance since they live an average of 110 miles from the cancer center. To address this potential barrier, a series of phase II clinical trials are underway to shorten the overall treatment duration, utililzing brachtherapy and tomotherapy for prostate and breast cancer, thereby, shortening the course of treatment form 6–8 weeks to 1–4. Sixty Phase II and III cooperative group trials are also open to address other malignancies. The identification of barriers which prevent Native Americans from presenting with earlier stages of cancer, or in some circumstances not at all, are under investigation through the administation of two surveys. Finally, it appears that NAs may be more sensitive to the effects of therapeutic radiation. To investigate this observation, a genetic study is underway where ATM (ataxia-telangiectasia mutation) heterozygosity is correlated to radiation toxicities. Preliminary results from all these studies will be presented. Through patient education, screening, assessing potential barriers to health care, and enrollment on innovative treatment strategies, it is anticipated that Native Americans will eventually present earlier in their disease process.
P1-025: Two cases of fatal hypoxemia after talc pleurodesis for malignant pleural effusion
Authors: Shin Ae Park, Han Hee Lee, Dae Jun Kim, Byoung Yong Shim, So Hyang Song, Chi Hong Kim, Myeong Im Ahn, Deog Gon Cho, Hoon Kyo Kim
Journal: Journal of Thoracic Oncology (2007)
Sufficient and Timely Autologous Stem Cell Harvest After Chemoimmunotherapy with Alemtuzumab In Combination with Bi-Weekly CHOP as First Line Treatment In Systemic Peripheral T-Cell Lymphomas (PTCL): a Feasibility Analysis From the First Randomized Trial In Systemic PTCL (ACT trial)
Authors: Francesco d'Amore, Maria Gomes da Silva, Sirpa Leppa, Antonio Pezzutto, Thomas Relander, Grete Fossum Lauritzsen, Eckhart Weidmann, Michel Van Gelder, Jeanette Doorduijn, J.C. Kluin-Nelemans, Marinus van Marwijk Kooy, Rob Fijnheer, Okke de Weerdt, Peter de Nully Brown, Per Boye Hansen, Mats Merup, Matthias Grube, Jose Mario Mariz, Jan Walewski, Lorenz Truemper, Gerald Wulf, Esa Jantunen, Georg Hopfinger, it Prochazka
Journal: Blood (2010)
Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions
Authors: Matthew A. Cavender, Deepak L. Bhatt, Gregg W. Stone, Harvey D. White, Ph. Gabriel Steg, C. Michael Gibson, Christian W. Hamm, Matthew J. Price, Sergio Leonardi, Jayne Prats, Efthymios N. Deliargyris, Kenneth W. Mahaffey, Robert A. Harrington
Journal: Circulation (2016)

Cangrelor is an intravenous P2Y12 inhibitor approved to reduce periprocedural ischemic events in patients undergoing percutaneous coronary intervention not pretreated with a P2Y12 inhibitor.
Misinformed debates on FGM can harm understanding
Authors: Susan Bewley
Journal: BMJ (2016)

The BMJ reports that nearly 6000 cases of female genital mutilation (FGM) were identified last year in the UK.1

The UK Female Genital Mutilation Act 2003 states that “A person is guilty of an offence if he excises, infibulates or otherwise mutilates the whole or any part of a girl’s labia majora, labia minora or clitoris.” …
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial
Authors: Andrew J Yee, William I Bensinger, Jeffrey G Supko, Peter M Voorhees, Jesus G Berdeja, Paul G Richardson, Edward N Libby, Ellen E Wallace, Nicole E Birrer, Jill N Burke, David L Tamang, Min Yang, Simon S Jones, Catherine A Wheeler, Robert J Markelewicz, Noopur S Raje
Journal: The Lancet Oncology (2016)